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Abstract
Purpose Radiation-induced rectovaginal fistula (RI-RVF) is a
chronic and serious condition with a significant influence on
quality of life. The aim of this study is to evaluate the results of
surgical treatment of rectovaginal fistulas of patients previous-
ly undergoing radiotherapy.
Methods Fifty patients treated in the Gynaecological
Radiotherapy Unit for gynaecologic malignancy and in the
Department of General and Colorectal Surgery for RI-RVF
between 2003 and 2013 were enrolled into a prospectively
maintained database and underwent regular follow-up exam-
inations in an outpatient clinic, during which surgical out-
comes were assessed.
Results Median age was 60 years (range 40–84 years).
Cervical cancer was the most common cause of radiotherapy.
Median time of fistula development after radiotherapy was
20 months (range 5–240 months). In 48 (96%) patients, only
faecal diversion could be performed, while two patients
underwent rectal resection. The fistula healed in six patients.
Factors that correlated with fistula healing were a distance
from the anal verge above 7 cm (p = 0.007 OR 18 95%CI
2.2609–14.3062) and creation of loop ileostomy (p = 0.08 OR
17 95%CI 1.2818–23.9701), whereas a prolonged course of
radiotherapy of more than 6 weeks (p = 0.047) correlated
negatively. In multivariate analysis, only distance from the
anal verge remained significant (p = 0.031 OR 2.35 95%CI
1.0422–5.2924).
Conclusions The treatment of radiation-induced rectovaginal
fistulas needs to be tailored individually to each patient.
Faecal diversion remains the simplest and safest method of
treating RI-RVF, especially in the group of patients who can-
not undergo complicated surgical procedures, and offers ac-
ceptable quality of life.
Keywords Rectovaginal fistula . Diverting stoma . Radiation
therapy
Introduction
Rectovaginal fistula is a serious anorectal condition with a
significant impact on patient quality of life. In recent years,
new options of surgical treatment have been introduced or
rediscovered, enabling improved treatment results, especially
when dealing with low fistulas [1, 2]. However, such progress
has not been observed in the field of Crohn-related and
radiation-induced RVF (RI-RVF), where the inflammatory re-
sponse and fibrosis of surrounding tissue limits the possibili-
ties of tissue healing, thus decreasing the number of possible
interventions [3–5]. Despite promising reports concerning the
use of collagen plugs and the Martius flap, insufficient studies
exist to properly assess the value of proposed methods, espe-
cially in the conditions mentioned below [6, 7]. Moreover, the
majority of RI-RVF patients are older, often with significant
comorbidities and decreased capability of applying postoper-
ative recommendations, which also negatively influences the
outcomes. Therefore, diverting colostomy is often the only
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possible treatment, allowing palliation of symptoms, a reduc-
tion of regional sepsis and improved tissue healing. Although
spontaneous closure of RI-RVF is rarely seen after faecal di-
version alone, the need for better local control of the disease
warrants further attempts to repair RI-RVFwith curative intent
[8].
The overall success rates for RI-RVF treatment vary from
18 to 93%, depending on the methods applied [4, 9–11].
However, drawing wider conclusions is limited, since the ma-
jority of the reported studies are based on analyses of relative-
ly small numbers of patients, often not exceeding 20 [12–14].
The present study assesses the results of RI-RVF treatment
and analyses the potential predictive factors of treatment out-




The Department of General and Colorectal Surgery, Medical
University of Lodz, Poland, is a regional tertiary referral cen-
tre and a national centre of excellence for colorectal diseases,
serving a population of about 3 million people. In 2003, after
institutional review board approval, the Rectovaginal Fistula
database was established to prospectively gather demographic
and clinical data based on established protocols.
Inclusion criteria and process
Each patient referred to the department with a diagnosis of
radiation-induced rectovaginal fistula was carefully examined
by a team of two colorectal surgeons (junior and senior) to
confirm the presence of RI-RVF and classify it, based on
diameter and distance from the anal margins, using a
rectoscope. RI-RVF was defined as the presence of an abnor-
mal canal between the rectum and the vagina, causing invol-
untary loss of faecal material and gas and intermittent dis-
charge of mucus through the vagina, which developed no
earlier than 90 days after completion of radiotherapy, after
the exclusion of other underlying ethiologies (i.e. IBD, cancer,
iatrogenic). The diameter of the fistula was defined as the
distance between two points located on the extremities of the
fistula opening in the rectum along its longer axis measured
during rectoscopy or in computed tomography studies.
Fistulas with a diameter smaller than 0.5 cm were considered
as small, between 0.5–2.5 cm as medium sized and larger than
2.5 cm as large.
To eliminate any possible bias in comparing different treat-
ment schemes, only patients with cervical and endometrial
cancer were included in the study. On the basis of a bilateral
agreement between Department and Gynaecological
Radiotherapy Unit, data concerning the course of oncologic
treatment for a particular patient was transferred to the data-
base and linked with medical records concerning
gynaecological treatment of the primary disease. Medical data
unrelated to the main diagnosis (comorbidities and remaining
medical history) was gathered from the patients based on dis-
charge letters. On this basis, the patient was qualified for sur-
gery. Positive treatment outcome was defined by the absence
of any vaginal discharge of faeces, flatus or mucous and the
absence of any visible fistula tract identified by computer
tomography (CT) of the abdomen with rectal contrast.
Persistence of clinical symptoms of rectovaginal fistula and/
or presence of fistula, confirmed by radiological studies (CT
with rectal contrast) after the operation was considered as a
negative outcome.
The exclusion criteria comprised the presence of RVF with
an aetiology which was not radiation induced (e.g. Crohn
disease), patients with active cancer or recurrence, and incom-
plete medical records.
Primary disease treatment
In order to compare administered radiation doses, for high-
dose rate (HDR) and low-dose rate (LDR), fractional doses
were presented as equivalent doses in 2 Gy fractions (EQD2).
Patients with cervical and endometrial cancer were treated by
intracavitary brachytherapy (ICBT) as HDR to the 35 Gy/5
fraction (EQD2 39.70 Gy) or LDR to the 54 Gy/3 fraction
(EQD2 58Gy) and external beam radiotherapy (EBRT) to
the 22 fraction of 2 to 44 Gy. Additionally, four doses of
cisplatin 50 mg/m2 were added during EBRT. The cumulative
radiation dose to point Awas around 84 Gy for no longer than
8 weeks. The adjuvant radiotherapy was routinely adminis-
tered also in cancer stage I patients with high-risk factors
including cancer histological type (other than adenocarcino-
ma), grade (grade 3), depth of myometrial invasion (stage IB)
and lymphovascular invasion (less than 10 nodes assessed).
Complications after radiotherapy were classified and graded
according to the Radiation Therapy Oncology Group scale
[15]. Acute complications were defined as developing during
treatment or within 90 days after its completion. Late compli-
cations were those occurring more than 90 days after the end
of treatment. Only grade III–IV complications were included
in the analysis. RI-RVF was not included in the grade 4 late
complication group, as this group was reserved for the com-
plications that coincide with RI-RVF. Tumours in stages IB1
to IIAwere initially treated with radical panhysterectomy and
removal of the lymph nodes.
Follow-up
Each patient was scheduled for follow-up visits in the
Departmental Outpatient Clinic (DOC) after 1 week and then
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1 month following discharge from hospital, and once a year
after that. Early surgical complications were defined as any
deviation from the normal postoperative course occurring
within 30 days following the operation, while late complica-
tions were those occurring after this period. When the pres-
ence of late complications was suspected, further visits were
organized. In the case of patients with disabilities or referrals
from distant regions, regular structured phone interviews were
performed in the periods stated above and results of the phys-
ical and radiological examinations performed in the health
institution local to the patient were sent to the department. In
2009 and in the end of the observation period (2015), all living
patients who remained in follow-up were examined in an out-
patient clinic by surgeons involved with the study.
Quality of life
As a part of an ongoing study concerning the quality of life of
patients with radiation proctopathy, all patients that were ex-
amined in 2015were asked to participate also in that study and
complete two questionnaires, i.e. standardized Satisfaction
with Life Scale (SWLS) and standardized Acceptance of
Illness Scale (AIS), adapted to Polish conditions by
Juczynski [16]. Only the key findings concerning the obtained
scores of the patients with RI-RVF are discussed in the present
study.
Statistical analysis
The collected data was entered by an encoder and checked for
integrity by another encoder. The data files were compared
and cross-checked for accuracy with the data collection forms
after every ten patients. The data was analysed using
STATISTICA (v.11 StatSoft, Inc., Tulsa OK, USA). Groups
were compared using either the t test, for normally-distributed
data, or the Mann-Whitney U test. Categorical variables were
analysed using the chi-squared or Fisher’s exact test with the
level of significance being P = 0.05. Frequencies (%) were




Fifty women were enrolled into the study. Demographic data
and data concerning the primary disease are shown in Table 1.
The median age of patients was 60 years (range 40–84 years)
and the majority of patients lived in urban areas.
Primary disease treatment
Twenty-seven patients (54%) underwent Wertheims-Meggs
panhysterectomy before radiation treatment. Twenty-three pa-
tients received radiotherapy within standard time frames and
doses. The median total dose of EBRT was 44 Gy (range:
31.4–52 Gy). The median dose per fraction was 2.0 Gy (range
1.8–2.0 Gy). The median total dose for HDR was EQD2
37.9 Gy (range 10.8–70 Gy) and for LDR was EQD2 58
(range 20.4–59.1 Gy). The median overall treatment time for
radiotherapy was 49 days (range 14–140 days). The most
frequent chemotherapy was concurrent delivery of cisplatin
(14 patients) or Taxol (7 patients).
Symptoms of grade 3 or 4 acute treatment-related toxicity,
as defined by the WHO, occurred in ten (17%) patients, in-
cluding anaemia in five patients, nausea and vomiting in three,
cystitis in three, and vomiting and diarrhoea in another three.
Eight (14%) patients demonstrated late treatment complica-
tions of grade 3 or 4 toxicity other than RI-RVF: radiation
enteritis, radiation cystitis, bowel obstruction, ileo-ileo fistula
and recto-vesical fistula.
Fistula characteristic
Median time from radiotherapy to fistula development was
20 months (range 5–240 months). The majority of fistulas
developed between 5 and 40 months, regardless of their loca-
tion (Fig. 1).
Median duration of symptoms was 1.5 months (range 0.2–
23 months). While 47 patients (94%) complained of passing a
stool through the vagina, the remaining 3 reported a history of
perianal pain, bloody discharges from the rectum and vagina
and vaginal infection.
In total, 13 fistulas were classified as low, 33 as medium and
11 as high. In 12 patients, the opening of the fistula in the rectum
could not be located during rectoscopy: the canal was further
than 9 cm above the anal verge in 7 patients, and the opening
of the fistula was smaller than 0.5 cm and could not be distin-
guished from the surrounding inflammatory tissue in 5. In ten
cases, the fistula was identified during radiographic studies and
in two cases by insertion of a tampon into the vagina followed by
instillation of a methylene blue enema. While fistula diameter
was less than 2.5 cm in 48 patients (80%), the opening in the
rectum was wider in the remaining cases, up to even 3.5 cm.
RI-RVF coexisted with a vesicovaginal fistula in three pa-
tients and with an intestinovaginal fistula in another three. In
another two patients, a vesicovaginal fistula developed in a
later postoperative course.
Treatment outcomes
By the end of the study, 22 patients were under observation
and 20 patients had died. In summary, eight patients were out
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of follow-up and could not be contacted. The course of obser-
vation is presented in Fig. 2. Among the living patients, 20
remained in follow-up in the outpatient clinic and another 2
were available for examination when prompted. Median fol-
low up in DOC was 2 years, whereas observation time was
3 years (range 1–15 years).
Faecal diversion alone was instigated in 97% of the pa-
tients. Two patients underwent lower anterior resection proce-
dure (LAR), the former with primary anastomosis and the
latter without.
The fistula healed spontaneously in six patients, with one
of whom underwent restoration of the digestive tract. In the






Age (range) 60 (40–84) 63 (45–72) 0.8875 60 (40–84)
BMI (range) 24 (15.6–33) 23 (21–31.3) 0.714 24 (15.6–33)
Smoking status
Current 15 (41.7%) 3 (50%) 0.261 20 (40.0%)
Former 21 (58.3%) 3 (50%) 30 (62.0%)






WBC (million cells/mcL) 9.09
(5.1–20.3)
6.61 (5.5–16.7) 0.242 9.37
(2.8–20.33)
ASA score
I–II 20 (55.6%) 5 (83.3%) 0.373 30 (60.0%)
III–IV 16 (44.4%) 1 (16.7%) 20 (40.0%)
Comorbidities (Charlson score)
0–2 23 (63.9%) 5 (83.3%) 0.645 35 (70.0%)
3–5 13 (36.1%) 1 (16.7%) 15 (30.0%)
Primary disease
Cervical cancer 25 (69.4%) 4 (66.7%) 0.615 37 (74.0%)
Endometrial cancer 11 (30.6%) 2 (33.3%) 13 (26.0%)
Staging (FIGO scale)
Ia 2 (5.6%) 0 (0%) 0.731 3 (6%)
Ib 6 (16.7%) 1 (16.7%) 0.690 9 (18%)
IIa 10 (27.8%) 2 (33.3%) 0.560 14 (28%)
IIb 8 (22.2%) 3 (50%) 0.313 12 (24%)
IIIa 3 (8.3%) 0 (0%) 0.621 3 (6%)
IIIb 7 (19.4%) 0 (0%) 0.566 10 (20%)
IVa 0 (0%)) 0 (0%) ----- 0 (0%)
IVb 0 (0%)) 0 (0%) ----- 0 (0%)
Histopathology
Adenocarcinoma 10 (27.8%) 2 (33.3%) 0.561 12 (24.0%)
Squamous cell 25 (69.4%) 4 (66.7%) 0.615 36 (74.0%)
Undifferentiated carcinoma 1 (2.8%) 0 (0.0%) 0.857 1 (2.0%)
Treatment
Surgery 21 (58.3%) 3 (50.0%) 0.519 27 (54.0%)
Chemotherapy 17 (47.2%) 4 (66.7%) 0.670 21 (42.0%)
Brachy and teletherapy 30 (83.3%) 4 (66.7%) 0.576 42 (84.0%)
Prolonged radiotherapy (more than 6 weeks) 18 (50.0%) 0 (0.0%) 0.029 18 (36.0%)
Reduced radiotherapy (less than 6 weeks) 5 (13.9%) 1 (16.7%) 0.629 6 (12.0%)
Only teletherapy 1 (2.8%) 0 (0.0%) 0.857 1 (2.0%)
Only brachytherapy 5(13.9%) 2 (33.3%) 0.567 7 (14.0%)
Early complications after radiotherapy grades
III–IV
10(27.8%) 0 (0.0%) 0.308 10 (20.0%)
Late complications after radiotherapy grades
III–IV
7 (19.4%) 1 (16.7%) 0.681 8 (16.0%)
RI-RVF treatment
Loop ileostomy 1 (2.8%) 2 (33.3%) 0.048 9 (18.0%)
End ileostomy 0 (0.0%) 0 (0.0%) – 1 (2.0%)
Loop transversostomy 21 (58.3%) 3 (50.0%) 0.519 24 (48.0%)
Loop sigmoideostomy 12 (33.3%) 1 (16.7%) 0.647 14 (28.0%)
Lower or Anterior resection 2 (5.6%) 0 (0.0%) 0.732 2 (4.0%)
Comorbidities were classified according to Charlson score
RI-RVF radiation-induced rectovaginal fistula, FIGO International Federation of Gynaecology and Obstetrics,
BMI body mass index, ASA American Society of Anaesthesiologists
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remaining five patients, the stoma was not reversed because of
high perioperative risk or the decision of the patient to not
undergo another operation. A summary of the patients is given
in Table 2.
Complications
Overall complications occurred in 43% of cases (25 patients):
22% (n = 13) being early and 28% (n = 16) late. One in-
hospital death occurred. A summary of the complications is
described in Table 3. Wound infection was the most common-
ly observed early complication (10%) and stomal prolapse the
most common late complication (14%).
Factors prognostic of treatment outcomes
Univariate analysis (Table 1) found distance from the anal
verge >7 cm (p = 0.007 OR 18 95%CI 2.2609–14.3062) and
creation of loop ileostomy (p = 0.08 OR 17 95%CI 1.2818–
23.9701) to significantly correlate with a positive outcome,
whereas a prolonged course of radiotherapy of over 6 weeks
(p = 0.047) correlated negatively. In multivariate analysis,
only distance from the anal verge remained significant
(p = 0.031 OR 2.35 95%CI 1.0422–5.2924; model signifi-
cance p = 0.01).
Quality of life
All living patients, who were examined at the end of the study
in 2015, agreed to complete the questionnaires. Among them
were 6 patients with repaired fistula and 14 patients with per-
sistent fistula.
Analysis of the AIS questionnaire showed a median score
of 27 (range 11–39), indicating moderate acceptance of the
disease by patients. The group with cured RI-RVF gave higher
scores, indicating good acceptance of illness (median 35 vs
27, p = 0.0814); however, this was found to be statistically
insignificant.
For the SWLS questionnaire, the median score from all
patients was 22 (range 15–32), indicating the respondents to
be generally satisfied with life. No patient was classified as
dissatisfied. The obtained scores did not differ statistically
between patients with and those without repaired fistula (me-
dian 22 vs 21, p = 0.5714).
Discussion
In 2014, nearly 100,000 people received radiation therapy for
gynaecological malignancies in the USA [17], at least, 4% of
whomwill develop radiation-induced rectovaginal fistula. It is
estimated that for every 1000 cancer cases in a population,
about 52% of patients need radiation therapy as an optimal
part of their management and a further 23% of this number
will require retreatment [18]. Recent decades have also seen a
progressive increase in disease-free survival, increasing the
numbers of patients who may develop RVF, long after onco-
logical treatment is finished. The actual numbers of patients
with RI-RVF are not easily available since there are no
population-based registries concerning RI-RVF worldwide.
That is why the scale of the problem may not be properly
perceived. Careful analysis of published reports concerning
radiotherapy for endometrial and cervical cancers which refer
to Polish population in the last decade reveals incidence of RI-
RVF in 3% of patients in analysed groups [19, 20]. We our-
selves have enrolled 50 patients for the participation in the
study from 1725 women who were treated with radiotherapy
for stages I–III of cervical and endometrial cancer with the
curative intent for the last decade in Regional Oncologic
Centre in Lodz. In this case, the incidence is estimated to be
about 3% too. It is generally agreed that doses above 70 Gy
cause significant and long-lasting injury to the surrounding
area [21] [22]. Although numerous factors have been identi-
fied increasing the risk of RI-RVF like advanced primary tu-
mour stage and elevated doses of radiotherapy to the rectum,
as well as the presence of cardiovascular comorbidities,
smoking and surgery or biopsy in the previously irradiated
field, the risk of RI-RVF development cannot always be mod-
ified by the patient or physician [14, 23–25]. Our findings
indicate that RI-RVF develops spontaneously, usually after
2 years following radiotherapy, and is not precipitated by ma-
jor events such as pelvic floor surgery or trauma.
The current literature affords little attention to the matter of
radiation-induced rectovaginal fistulas. Moreover, no reliable
clinical trials have yet been published concerning the
Fig. 1 Time from radiotherapy and location of RI-RVF in patients with
and without healed RI-RVF. Patients with healed RI-RVF are marked. A
marked difference was found in distance from anal verge between
patients with healed RI-RVF and patients with persistent RI-RVF
(p = 0.008 95% OR 26.67 Cl 2.18–32.47)
Langenbecks Arch Surg
efficiency of available treatment options [7]. Numbers of pa-
pers concerning treatment of RVF of different origins presents
a variety of techniques available to use, both from perianal and
abdominal approach. Success rates in such operation varied
from 25 to 100% and often rise after repeated surgery [10, 12,
14, 26]. Which of them refers to RI-RVF? D’Ambrosio et al.
report the results of RVF treatment with transanal endoscopic
microsurgery (TEM) in a group of 13 patients [27]. The ap-
proach led to fistula healing in 12 patients, but the only one not
healed had radiation-induced RVF, with two relapses follow-
ing treatment. After a further unsuccessful treatment of the
relapse with TEM and the presence of another relapse, the
patient refused another attempt and maintained her ostomy.
In 2007, McNevin achieved a healing rate of 96% when using
the Martius flap. However, none of the patients had experi-
enced RI-RVF and post-procedural dyspareunia was also
observed [6]. In a systematic review of other literatures and
his own experience (2008), Wexner reports a success rate of
73.5% (range 33–100%) with 81.8% of stoma closures after
gracilis muscle interposition [14]. Complications were present
in 29% and this often demandedmore than one repair. Authors
claimed that such results were harder to achieve in the inflam-
matory bowel disease and radiation group. Also, the use of
plugs and fibrin glue in RI-RVF is not recommended, since
short and frequently epithelialized canal of the fistula is not
suitable for such modality [10]. In all of the reports, patients
with RI-RVF comprised usually not more than 20% of the
analysed patients. Among the operations from the abdominal
approach that have been proved to be useful in treating RI-
RVF, coloanal sleeve anastomosis and the Bricker-Johnston
sigmoid colon graft were applied in a larger group of patients,
though majority of the reports were published around 1980–





























































































































































































































































































































































































































































































































































































































































1990. Coloanal sleeve anastomosis, first described by Parks
and colleagues in 1978, is used now occasionally to treat
rectovaginal fistulas [28]. However, in 1986, Cooke and
Wellsted achieved healing of the post-radiation fistula in 55
of 59 patients (93%) and Nowacki reported good functional
outcomes in 18 of 24 patients with RI-RVF, treated over a 10-
year period [9, 29]. Bricker-Johnston sigmoid colon graft [30]
and its modification proposed by Steichen [31] was success-
fully applied in a 61-year-old female with RI-RVF with good
functional results but following the three-stage procedure.
More recently, Zimmermann described the ultra-deep anterior
rectum resection with transperineal and transvaginal omentum
reconstruction coupled with protective ileostomy construction
that his team used to treat a 37-year-old woman with RI-RVF
[32]. Authors of these reports observed that the described
techniques are efficient in cases of high fistulas and empha-
sized the careful selection of patients fit for the procedures.
Both of the observations are confirmed in our study. The only
factor significant in multivariate analysis was a high location
of the fistula that correlates positively with spontaneous RI-
RVF healing. Although statistical strength could not be high
for the analysed cohort, the fact that high fistula is more prone
to heal seems to be obvious. This may be attributed to a num-
ber of possible causes. In these patients, the sphincter
mechanism is usually not impaired significantly and anasto-
mosis can be made 1–2 cm above the dentate line, giving
better functional outcomes and possibility to perform resec-
tion and/or interposition of healthy tissue. Recently, the role of
colonic bacteria in the upper part of the rectum is postulated as
a factor fostering healing. Colonic bacteria are known to pro-
duce short-chain fatty acids (SCFAs), which are the main ox-
idative fuel for the colonic mucosa and have a trophic effect
on the rectal mucosa stimulating mucosal blood flow [33]. We
observed 11 patients with high fistulas and in 3 patients fistula
healed spontaneously. In general, we performed lower anterior
resection in two patients. In the remaining cases, the creation
of a faecal diversion and occasional simple suturing of the
fistula canal was applied. This in turn refers to second issues
discussed by authors mentioned above. In nearly 80% of our
patients, the presence of adhesions was observed, often ac-
companied by inflammatory changes in the pelvis. That is
why, resections were not safe and even diverting stoma had
to be made on the transverse colon instead of the sigmoid
colon. One might ask why we refrained from performing the
procedures described above and limited ourselves to creation
of faecal diversion only. First of all, the creation of diverting
stomy gives the immediate relieving of symptoms and enables
the damaged area to heal, thus preparing the patient for the
Table 3 Complications in patients with radiation-induced rectovaginal fistulas
Type of complication Patients with healed rectovaginal
fistula




Early 2 (33.3%) 9 (25.0%) 11
(22.0%)
0.503
Wound infection 1 (16.7%) 3 (8.3%) 4 (8.0%) 0.474
Eventration 1(16.7%) 1 (2.8%) 2 (4.0%) 0.268
Bowel/Stoma obstruction 0 (0.0%) 1 (2.8%) 1 (2.0%) 0.857
Systemic complications 0 (0.0%) 3 (8.3%) 3 (6.0%) 0.621
Other 0 (0.0%) 4 (11.1%) 4 (8.0%) 0.526
Late 2 (33.3%) 11 (30.6%) 13
(26.0%)
0.615
Stoma prolapse 1 (16.7%) 6 (16.7%) 6 (12.0%) 0.743
Stoma stricture 0 (0.0%) 4 (11.1%) 4 (8.0%) 0.526
Parastomal hernia 1 (16.7%) 2 (5.6%) 3 (6.0%) 0.378
Parastomal ulceration 0 (0.0%) 1 (2.8%) 1 (2.0%) 0.857
Bowel obstruction 0 (0.0%) 1 (2.8%) 1 (2.0%) 0.857
Other 1 (16.7%) 2 (5.6%) 3 (6.0%) 0.378
Presence of early and late complications 1 (16.7%) 2 (5.6%) 3 (6.0%) 0.378
Mortality 0 (0.0%) 17 (47.2%) 17
(34.0%)
0.065
In-hospital mortality 0 (0.0%) 1 (2.8%) 1 (2.0%) 0.857
Related to primary disease and RVF treatment 0 (0.0%) 7 (19.4%) 7 (14.0%) 0.309
Unrelated to primary disease and RVF
treatment
0 (0.0%) 10 (27.8%) 10
(20.0%)
0.308
Other early complications: episode of postoperative fever above 38 °C without known underlying cause, decrease in Hg value without signs of active
bleeding, urinary bladder lesion. Other late complications: intra-abdominal abscess, stenosis of the rectum, phlegmon of the anterior abdominal wall
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potential further intervention. Despite loop colostomy being
advantageous in patients with significant comorbidities and
severe local inflammation due to low rates of postoperative
complications and the relatively small surgical intervention,
the complications did appear and were the reason for
reoperations in 15% of the patients (Table 3). Although the
majority of them were late and related to stoma, it could
prompt the idea that these patients may be of higher risk for
developing complications. Only one patient died in the hospi-
tal, but 41% of all deceased patients in follow up were due to
cancer and RI-RVF treatment. For this reason, the authors
repeatedly consulted surgeons from well-known colorectal
departments abroad, which sustained the decision of not
performing more advanced procedures. Not only do current
oncological status, patient age, location of the fistula in the
rectum, the presence of comorbidities and local tissue status
determine the available treatment but also the ability to follow
up the postoperative recommendation. Such factors dimin-
ished the numbers of patients fitted for surgery, which explain
why only 20% of the patients mentioned in new reports are
those with RI-RVF. The incidence of RI-RVF remains similar
amongWestern countries, but patients who were not qualified
for reconstructive procedures are not counted in the papers.
Authors of the study performed various procedures including
Martius flap and gracilis muscle interposition with good func-
tional outcomes but in cases of RVF after delivery or trauma.
This is a reason why loop colostomy comprised the majority
in the analysed cohort. On the other hand, faecal diversion
alone rarely leads to spontaneous closure of the fistula [8].
Loop colostomy was treatment of choice in the current study,
also to give the patient the opportunity for easier stoma rever-
sal in the future, which was achieved in one patient. Patients
underwent essential examinations (computed tomography and
colonoscopy) to rule of recurrence, confirm the closure of RI-
RVF and check the large bowel for the presence of strictures or
s tenosis . Final ly, the pat ients were assessed by
anaesthesiologists for their fitness for operation, referring pa-
tient to specialist (cardiologist, endocrinologist) when neces-
sary. The risk and benefits of the procedure were also widely
discussed. The procedure was performed with open access but
utilizing the stoma opening and postoperative course was un-
eventful. However, five patients did not want to undergo an-
other operation. All these raise the question of whether any
pretreatment indicators of outcome can be found. Patient age
and general health status (expressed in ASA and Charlson
score, BMI and smoking status), though possibly indirectly
contributing to tissue condition, were not significant predic-
tors of RI-RVF healing. On the other hand, these variables are
usually taken into account when qualifying the patient for a
particular operation; they therefore may well be related to
perioperative risk and the development of complications rath-
er than to directly influence the outcomes of RI-RVF repair. In
fact, the main advantage of the perianal procedures is the lack
of any significant perioperative morbidity, whereas the place-
ment of viable tissue is usually possible during procedures
from the abdominal approach. Still, the main contraindication
for the abdominal operations is the significant risk of periop-
erative complications. The laparoscopic approach may be an
optimal solution in this regard; however, it has only been used
in a few case studies [13, 34]. Further studies involving larger
numbers are warranted, especially in groups with RI-RVF, to
provide clear evidence that laparoscopic approaches are safe
and beneficial in this group of patients.
Limitations and strengths
This is so far the largest study analysing the surgical outcomes
of RI-RVF treatment and was based on careful data acquisi-
tion and a long follow up. However, due to the general health
status of the patients and the decision of the surgeon, only
faecal diversion and standard resection were instigated in
treatment, either with or without coloanal anastomosis, which
excluded the varieties of other techniques described above.
Although such operations are performed in our department
for RVF of different aetiologies, they were not recommended
for that particular group. Hence, this study serves as a remind-
er that most approaches to treating RI-RVF may be used only
in a limited number of patients, where local tissue viability and
a satisfactory general condition allow their use. However, in a
number of patients, a fecal diversion will improve symptoms
and their quality of life to the point that they do not require any
further intervention even though the underlying problem is not
repaired.
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